RPS4X and neoplasm: A study has shown that SLFN11 can act as a tumor suppressor by suppressing the mTOR pathway by targeting RPS4X in hepatocellular carcinoma, which suggests that its mutation may lead to the loss of its inhibitory effect on mTOR [20].